ストックスクリーナーアプリを入手
814.17
2.47%
-20.58
アフターアワーズ：
814.16
-0.010
-0.00%
前日終値:
$834.75
開ける：
$838.27
24時間の取引高:
670.52K
Relative Volume:
1.78
時価総額：
$49.83B
収益：
$3.06B
当期純損益:
$1.28B
株価収益率:
41.39
EPS:
19.6719
ネットキャッシュフロー:
$447.35M
1週間 パフォーマンス:
-0.18%
1か月 パフォーマンス:
+10.02%
6か月 パフォーマンス:
+35.72%
1年 パフォーマンス:
+43.22%
1日の値動き範囲:
$813.30
$839.66
1週間の範囲:
$813.30
$855.46
52週間の値動き範囲:
$510.06
$855.46
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-15 | 再開されました | Truist | Buy |
| 2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
TD Cowen Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
argenx stock price target maintained at $800 by TD Cowen on strong Vyvgart uptake - Investing.com
Argenx Se (ARGX) Gets a Buy from Evercore ISI - The Globe and Mail
How Do Investors Really Feel About argenx SE? - Sahm
RBC Capital Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
Argenx NV stock hits all-time high at 803.95 USD By Investing.com - Investing.com South Africa
Argenx NV stock hits all-time high at 803.95 USD - Investing.com
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025 - The Globe and Mail
Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX) - The Globe and Mail
Argenx stock hits all-time high at 781.12 USD By Investing.com - Investing.com Australia
Argenx stock hits all-time high at 781.12 USD - Investing.com
Argenx Se (ARGX) Gets a Buy from Morgan Stanley - The Globe and Mail
Argenx Se (ARGX) Receives a Buy from RBC Capital - The Globe and Mail
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
Price Over Earnings Overview: argenx - Sahm
Leerink Partners Keeps Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Oppenheimer reaffirms Outperform rating on argenx stock after positive data - Investing.com
Truist Securities reiterates Buy rating on argenx stock with $918 target - Investing.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Truist Securities assumes coverage on argenx stock with Buy rating - Investing.com
Deutsche Bank downgrades Argenx to “hold” after 40% rally, €655 PT intact - Investing.com
14 Newly Overvalued Stocks for the Week - Morningstar
BofA Securities reaffirms Buy rating on argenx stock with $887 target - Investing.com
Argenx stock hits all-time high at 716.89 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Piper Sandler raises argenx stock price target to $820 on Vyvgart success - Investing.com
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx stock reaches all-time high at 696.94 USD - Investing.com
Argenx: study met primary endpoint - AInvest
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis - Sahm
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa
BofA Securities raises argenx stock price target to $880 on strong Vyvgart sales - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
BofA Securities raises argenx stock price target to $829 on Vyvgart growth - Investing.com
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
Argenx stock price target reiterated at $761 on positive trial data - Investing.com
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
1.92%
大文字化:
|
ボリューム (24 時間):